Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02755545 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments
A Phase 4 study of Acne, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
- 1
- Study location
NCT02755545: Completed Phase 4 study of Acne, sponsored by Galderma R&D.
NCT02755545 is a Phase 4 study of Acne that has completed, run by Galderma R&D. The registered enrollment target is 127 participants, roughly in line with the 138-participant average among 26 other Acne trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02755545, a Phase 4 study of Acne, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of 2 acne treatments for 24 weeks of use in adult men and women with mild to moderate facial acne, at least 5 inflammatory lesions, and at least 10 - 100 non-inflammatory lesions.
Primary Outcome
Percent change from baseline in total lesions at week 12 was assessed by investigator or designee. Investigator or designee counted and recorded the number of open comedones, closed comedones, papules, and pustules on each subject's face. Lesions were counted globally on the following facial locations/quadrants: forehead, left cheek, chin, and right cheek. Each of the following lesion types were analyzed separately for forehead, left cheek, chin, right cheek, and the total of the 4 areas: * Inf
Conditions Studied
Interventions
- DRUG Product A
- DRUG Product B
Study Locations (1)
Texas
- Stephens & Associates, Inc. Texas Research Center - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2017-04-04 |
| Phase | Phase 4 |
What the finished NCT02755545 record still lists
NCT02755545 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 138-participant average among 26 other Acne trials with a reported enrollment target.
The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 2 interventions - of which Product A is the first listed.
NCT02755545 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02755545 about?
NCT02755545 is a clinical study titled "A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments". The purpose of this study is to evaluate the efficacy of 2 acne treatments for 24 weeks of use in adult men and women with mild to moderate facial acne, at least 5 inflammatory lesions, and at least 10 - 100 non-inflammatory lesions.
What is the current status of trial NCT02755545?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2016-05-01. Estimated completion is 2017-04-04.
What conditions does trial NCT02755545 study?
This clinical trial studies the following conditions: Acne.
What interventions are being tested in trial NCT02755545?
The interventions under investigation include: Product A (DRUG), Product B (DRUG).
Who is sponsoring clinical trial NCT02755545?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02755545 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02755545's enrollment target sits among peer trials
127 9th of 26 higher than 18 of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne
ACTIVE NOT RECRUITING · Phase 4
-
Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%
COMPLETED · Phase 4
-
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
COMPLETED · Phase 4
-
Profiling the Skin Microbiome in Response to Altreno in Acne Patients
COMPLETED · Phase 4
-
Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline
COMPLETED · Phase 4
-
Comparison Study of Topical Acne Regimens
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI